De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Sino Biopharmaceutical Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
Sino Biopharmaceutical heeft een totaal eigen vermogen van CN¥42.1B en een totale schuld van CN¥9.5B, wat de schuld-eigenvermogensverhouding op 22.6% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥66.7B en CN¥24.6B. De EBIT Sino Biopharmaceutical is CN¥5.9B waardoor de rentedekking -22.2 is. Het heeft contanten en kortetermijnbeleggingen van CN¥13.2B.
Belangrijke informatie
22.6%
Verhouding schuld/eigen vermogen
CN¥9.51b
Schuld
Rente dekkingsratio | -22.2x |
Contant | CN¥13.18b |
Aandelen | CN¥42.12b |
Totaal verplichtingen | CN¥24.58b |
Totaal activa | CN¥66.70b |
Recente financiële gezondheidsupdates
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
Sep 02Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
May 21Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?
Dec 02We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease
Aug 30Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet
Apr 20Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
Oct 24Recent updates
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
Sep 02Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?
Jul 12Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
May 21Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings
Apr 21What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates
Apr 03Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 20Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon
Dec 18Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?
Dec 02Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate
Nov 17We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease
Aug 30Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?
May 26Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet
Apr 20Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?
Feb 09Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Nov 11Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
Oct 24Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?
Jul 08Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?
Apr 28Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( CN¥25.2B ) 1177 } overtreffen de korte termijn passiva ( CN¥21.9B ).
Langlopende schulden: De kortetermijnactiva 1177 ( CN¥25.2B ) overtreffen de langetermijnschulden ( CN¥2.6B ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 1177 heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van 1177 is de afgelopen 5 jaar gestegen van 8.2% naar 22.6%.
Schuldendekking: De schuld van 1177 wordt goed gedekt door de operationele kasstroom ( 68.1% ).
Rentedekking: 1177 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.